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Objective: The aim of the present study was to determine if the electroporation-mediated gene transfer of
SOX trio enhances the chondrogenic potential of adipose stem cells (ASCs).
Design: ASCs were transfected with SOX trio genes using an electroporation technique and cultured for
3 weeks. The pellets were analyzed for DNA and glycosaminoglycan (GAG) analysis, and the gene and
protein expression of SOX-5, SOX-6, SOX-9, type 1 collagen (COL1Al), type 2 collagen (COL2Al) and type
10 collagen (COL10A1) using real-time PCR and Western blot analysis. Further in vivo studies were
carried out by subcutaneous transplantation of pellets in severe combined immunodeﬁciency (SCID)
mice for 3 weeks.
Results: The gene transfer efﬁciency was high (approximately 70%). Transfected ASCs showed high
expression of corresponding genes after 21 days, and each SOX protein was detected in ASCs transfected
with the corresponding gene. The chondrogenic differentiation of ASCs, as demonstrated by GAG levels
and Safranin-O staining, showed signiﬁcant enhancement when SOX trio were co-transfected, while
subsets with single gene transfer of SOX-5, -6, or -9 did not show signiﬁcant elevation. SOX trio co-
transfection enhanced COL2A1 mRNA, but did not increase COL1A1 and COL10A1 mRNA. Type II collagen
protein dramatically increased, and type X collagen decreased with co-transfection of the SOX trio. When
pellets were implanted in the subcutaneous pouch of SCID mice for 3 weeks, ASCs co-transfected with
SOX trio demonstrated abundant proteoglycan, signiﬁcantly reduced mineralization.
Conclusion: The electroporation-mediated transfection of SOX trio greatly enhances chondrogenesis from
ASCs, while decreasing hypertrophy.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Injury of articular cartilage (AC) in adults usually leads to oste-
oarthritic changes of the joint because AC has a limited capacity for
self-repair1. Cell-based therapy is currently the mainstay of efforts
to regenerate AC. However, the use of autologous chondrocytes that
have been popularized in recent decades has some limitations,
including donor site morbidity and dedifferentiation of chon-
drocytes2,3. These shortcomings have prompted further investiga-
tions to ﬁnd other sources that would offer an abundant number of
self-replenishing cells4,5.
Mesenchymal stem cells (MSCs) have a pluripotential capacity,
which allows them to differentiate into a variety of connective: Gun-Il Im, Department of
Siksa-Dong, Goyang 411-773,
61-7314.
s Research Society International. Ptissue lineages, including bone, cartilage, fat, and muscle6e9. The
potential of MSCs for self-replication and differentiation provides
therapeutic opportunities for the treatment of musculoskeletal
defects. Although bone marrow is the best known source of MSCs,
adipose tissue offers the most abundant and easily accessible pool
of MSCs10e12. Adipose stem cells (ASCs) obtained from lipoaspirates
have multi-lineage potential to differentiate into adipogenic,
chondrogenic, myogenic, and osteogenic cells11,13,14. However,
several studies, including one from our group, noted that ASCs had
lower chondrogenic potential using a combination of growth
factors currently known to induce chondrogenesis of MSCs from
bone marrow15e18. Despite the reportedly poor response of ASCs to
chondrogenic signals, ASCs merit further investigation because of
their acquisition advantage. We had investigated the conditions for
growth factor application, ﬁnding that either high-dose trans-
forming growth factor (TGF)-b plus insulin-like growth factor (IGF)-
I or a combination of TGF-b plus bone morphogenetic protein
(BMP)-7 was effective in inducing chondrogenic differentiation of
ASCs19,20. One of the dilemmas in inducing chondrogenesis fromublished by Elsevier Ltd. All rights reserved.
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signiﬁes inadequate differentiation and hypertrophy, respectively.
Several lines of evidence indicate the signiﬁcance of SOX tran-
scription factors for the maintenance of chondrocytic pheno-
types21,22. These factors belong to a family of regulatory molecules
related to sex-determining factor SRY (sex-determining region Y)23,
which is expressed in all chondrogenic cells, except hypertrophic
chondrocytes21. SOX-9 binds and activates other chondrocyte-
speciﬁc enhancer-elements in COL2A1, COL9A1, COL11A2, and
aggrecan in vitro2427. Two other members of the SOX family (SOX-5
and SOX-6) are also required for perfect chondrogenesis, which are
co-expressed with SOX-9 in all chondroprogenitors and differen-
tiated chondrocytes, and cooperated with SOX-9 to activate COL2A1
gene21,28,29. Previous studies have also reported on SOX gene
transfers to induce chondrogenesis in human embryonic stem cells
and ﬁbroblast, and to promote chondrogenesis from murine
MSCs30,31. However, the effect of SOX trio gene transfer on human
ASCs has not been reported.
With these limitations of growth factors in inducing chondro-
genesis from ASCs, and previous investigations reporting enhanced
chondrogenesis and inhibition of hypertrophy in a variety of cells
by gene transfer of SOX trio, we reasoned that gene transfer of these
genes would enhance chondrogenesis from ASCs. As viral gene
transfer methods are associated with the risk of immunologic
reactions and mutagenesis32e34, these methods are not indicated
for the treatment of non-lethal disease. As the purpose of gene
transfer of the SOX trio is for cartilage tissue engineering, non-viral
methods should be used if considered for clinical applications.
Thus, in this study, we tested the hypothesis that non-viral trans-
fection of the SOX trio gene would signiﬁcantly enhance the
chondrogenic potential of ASCs. We used a microporation method,
which has a capillary tip and pipette-based gene transfer tech-
nique34. This technique is known to circumvent a number of
harmful effects of a cuvette-based electroporation method, such as
pH variation, temperature rising, turbulence, and metal ion
generation35. Microporation provides an easier and more efﬁcient
method for hard-to-transfect cells with its high transfection efﬁ-
ciency and reproducibility35. Therefore, the present study was
embarked upon an endeavor for electroporation-mediated non-
viral gene transfer of SOX trio in human ASCs.
Materials and methods
Sample procurement
The adipose tissue samples were isolated from the lipoaspirates
generated during elective liposuction procedures on ﬁve patients
(mean age, 41 years; range, 36e55 years). This study was approved
by the Institutional Review Board at our university, and informed
consent was obtained from all the individuals included in the study.
Cell isolation and cultivation
ASCs were isolated from lipoaspirates, then expanded as
described in previous studies11,17. Cells were cultured in Dulbecco’s
modiﬁed Eaglemedium (DMEM)/F-12 supplementedwith 10% fetal
bovine serum (FBS; Invitrogen/GIBCO, Grand Island, NY, USA) and
1% antibiotics, and maintained at 37C for 48 h in a 5% CO2
humidiﬁed atmosphere. Cells were then washed with phosphate
buffered saline (PBS; Welgene, Daejeon, Korea) to remove non-
adherent material. During the expansion period, medium was
replaced twice per week. When cells reached 80% conﬂuence, they
were detached from culture dishes using 0.25% trypsin containing
1 mM ethylenediaminetetraacetic acid (EDTA; Gibco BRL Green
Island, NY, USA) washed with PBS, counted, and re-plated. Afterculturing through passage 2, cells were suspended in a cryopres-
ervation medium containing 90% FBS and 10% dimethylsulfoxide.Construction of plasmids
The coding regions of human SOX-5, SOX-6, and SOX-9 from the
NIH Mammalian Gene Collection (MGC) cDNA Clones (Invitrogen
Corporation, Carlsbad, CA, USA) were ampliﬁed by polymerase
chain reaction (PCR) and cloned into pECFP-C1 expression vectors
(Clontech, Palo Alto, CA, USA). In order to increase cloning efﬁ-
ciency, the 50 end was made sticky and the 30 end was made blunt.
After PCR, the insert was prepared using enzymes (SmaI and BglII;
Takara Bio Inc., Otsu, Japan). SmaI was applied to digest the 30 end,
followed by T7 polymerase (Takara Bio Inc.), which induced the
blunt end. BglII was used to produce a sticky 50 end. For the vector,
SmaI and BglII were used for the same purpose. The prepared vector
and insert underwent ligation using Ligation Mix (Takara Bio Inc.),
and underwent transformation to obtain the respective clones. The
PCR products were veriﬁed by DNA sequencing.Transfection by electroporation
Sub-conﬂuent ASCs were harvested and washed with PBS. Cells
were resuspended in resuspension buffer R at a density of
3105 cells/ml and mixed with 0.5 mg plasmids. Then, electro-
poration was performed with a Microporator (Invitrogen) using
programs recommended by the manufacturer (1400 V for 20 ms).
After electroporation, cells were plated onto a 12-well plate and
placed at 37C in 5% CO2. Six subsets were prepared, as follows: #1,
ASCs transfected with pEGFP-C1 without interposed genes
of transcription factors (negative control); #2, ASCs transfected
with pEGFP-C1 interposed with SOX-5 gene; #3, ASCs
transfected with pEGFP-C1 interposed with SOX-6 gene; #4,
ASCs transfected with pEGFP-C1 interposed with SOX-9 gene; #5,
ASCs transfected with one-third doses (0.17 mg) of each plasmid
(SOX-5, -6, -9); #6, ASCs treated with a combination of 5 ng/ml of
TGF-ß2 and 100 ng/ml of BMP-7 (positive control group), which are
based on our previous study19.Conﬁrmation of gene transfer efﬁciency using ﬂuorescence
microscopy and ﬂow cytometry
After performing gene transfer, the transfection efﬁciency of
each genewas conﬁrmed using ﬂuorescencemicroscopy (Leica DMI
6000B; Wetzlar, Germany) and ﬂow cytometry (Beckman Coulter
Inc., Fullerton, CA, USA) 24 h after transfection. For ﬂow cytometry,
the cells were thrice washed and suspended in a media consisting
of Hank’s Buffered Salt Solution (HBSS; Welgene) with 2% FBS
(Invitrogen/GIBCO). The ASCs that were not used for gene transfer
were used as the negative control. Thereafter, the cells were
analyzed using CXP software (Beckman Coulter Inc.).Pellet culture
Transfected ASCs were cultured in DMEM/F-12 supplemented
with 1% insulin-transferrin-selenium (ITS), 107 M dexamethasone,
50 mM ascorbate-2-phosphate, 50 mM L-proline, and 1 mM sodium
pyruvate. For pellet cultures, 2.5105 cells suspended in 500 ml of
culture medium were aliquoted into 15 ml polypropylene centri-
fuge tubes, and spun in a benchtop centrifuge at 500g for 10 min.
The tubes were then placed in an incubator at 37C in a humidiﬁed
95% air/5% CO2 atmosphere. The medium was changed every third
day. The pellet culture was carried up to 3 weeks.
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Thepellets of eachgroupwere digested overnight inpapainbuffer
at 60C. The DNA content was determined using the Quant-iT
dsDNA assay kit and the Qubit Fluorometer system (Invitrogen). GAG
production was determined using a Blyscan Kit (Biocolor, Carrick-
fergus, UK), according to the manufacturer’s instructions. GAG levels
were expressed as micrograms of GAG per microgram of DNA.Reverse transcription and real-time PCR analysis
Total RNA from cells were isolated with an RNeasy Mini Kit
(Quiagen, Hilden, Germany), according to the manufacturer’s
instructions, then quantiﬁed using the Quant-iT RNA assay kit
and the Qubit Fluorometer system (Invitrogen). All total RNA
samples were treated with DNAse I (Quiagen). Total RNA was
reverse-transcribed with Multiscribe reverse transcriptase (Invi-
trogen) oligo (dT) primer in a 40 ml reaction volume, according to
the manufacturer’s instruction. All the PCR reactions were per-
formed on the LightCycler 480 system (Roche Diagnostics, Man-
nheim, Germany) in standard 10 ml reactions, as follows: 4.5 ml
(10 ng) cDNA, 0.5 ml of 10 mM sense primer, 0.5 ml of 10 mM anti-
sense primer and 4.5 ml LightCycler 480 SYBR Green I Master mix
(Roche Diagnostics). The primers and conditions for SOX-5, SOX-6,
SOX-9, type 1 collagen (COL1A1), type 2 collagen (COL2A1), and
type 10 collagen (COL10A1), are listed in Table I. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as an internal
control for PCR ampliﬁcation and the relative normalization ratio of
PCR products derived from each target gene was calculated using
software of the LightCycler System. All experiments were per-
formed in triplicate.Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and Western blotting
To conﬁrm the translation of SOX-5, -6, and -9 and chondrogenic
gene expression at the protein level, protein extracts were analyzed
by Western blotting for SOX-5, SOX-6, SOX-9, and types I, II and X
collagen. Brieﬂy, cells were washed twice with cold PBS, and sus-
pended in 50 ml of radioimmunoprecipitation assay (RIPA) lysis
solution (Pierce, Rockford, IL, USA), according to the manufacturer’s
instructions. The protein concentration was determined using
a Qubit assay kit (Invitrogen) and equal amount of protein extracts
was fractionated by 10% SDS-PAGE (Bio-Rad, Hercules, CA, USA),
and transferred onto a BioTrace NT Nitrocellulose Transfer
Membrane. After blocking with Tris-buffered saline (TBS)-T (10 mM
Tris; 150 mM NaCl, and 0.05% Tween-20) containing 3% non-fatTable I
Primers used for real-time PCR
Gene symbol Sequences (50e30) Accession no.
COL1A1 F-CCGCCGCTTCACCTACAGC NM_000088
R-TTTTGTATTCAATCACTGTCTTGCC
COL2A1 F-ATAAGGATGTGTGGAAGCCG NM_001844
R-TTTCTGTCCCTTTGGTCCTG
COL10A1 F-CAGTCATGCCTGAGGGTTTT NM_000493
R-GGGTCATAATGCTGTTGCCT
SOX-5 F-CAAGGCAATCCAAGAAGCTC AB_081589
R-CCAATCATTGCATGGCTAAA
SOX-6 F-AGGATCTCGCTGGAAATCAA AF_309034
R-CTGCCTCATCTCCTGTCTCC
SOX-9 F-GGAGCTCGAAACTGACTGGAA NM_000346
R-GAGGCGAATTGGAGAGGAGGA
GAPDH F-CACATGGCCTCCAAGGAGTAA NM_002046
R-GTACATGACAAGGTGCGGCTCpowdered milk (Bio-Rad Laboratories, Inc, Gothenburg, Sweden),
the blots were incubated with speciﬁc primary antibody for 2 h at
room temperature, washed, and incubated with secondary anti-
body for 1 h at room temperature, then washed again. The blots
were developed using the SuperSignal West Pico Chemilumines-
cent Substrate (Pierce) following the manufacturer’s protocols.
After three washes, the protein bands were visualized with an
enhanced chemiluminescence (ECL) Western blot analysis system
(Amersham Biosciences, Piscataway, NJ, USA). Primary antibodies
were rabbit type I collagen polyclonal antibody (Millipore, Billerica,
MA, USA), mouse type II collagen monoclonal antibody (Millipore),
mouse anti-human type X collagen monoclonal antibody (Sigma-
eAldich, St. Louis, MO, USA) and rabbit SOX-5, SOX-6, and SOX-9
polyclonal antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA) diluted 1:200 in TBS-T/2.5% non-fat dry milk. Secondary
antibody was horseradish peroxidase (HRP)-conjugated goat anti-
rabbit, goat anti-mouse IgG antibody diluted 1:2000 (Santa Cruz
Biotechnology, Inc.) in TBS-T/2.5% powdered non-fat dry milk. This
experiment was repeated in three samples, each from different
persons.
Subcutaneous transplantation in severe combined
immunodeﬁciency (SCID) mice
Pellets of subsets #1 and #5 (n¼ 3) were cultured as an in vitro
pellet culture for 7 days, then transplanted into subcutaneous
pockets in the upper dorsal area of anesthetized SCID mice. Pellets
were attached to a non-absorbable surgical suture ﬁxed with ﬁbrin
glue to facilitate recovery at the time of harvest. Six subcutaneous
pouches prepared on the backs of each male SCID mice. Samples
were explanted 3 weeks after implantation, and analyzed for GAG,
calcium contents, and histology.
Measurement of calcium content from harvested pellets
The harvested pellets of each group were added with 100 ml of
lysis buffer (RIPA; Thermo, Rockford, IL, USA) and homogenized
with liquid nitrogen. The lysate was maintained for 2 h, then
centrifuged for 20 min at 12,000 rpm in a microcentrifuge. Calcium
Colorimetric Assay Kit (Biovision, Mountain View, CA, USA) was
used to measure the calcium contents from the supernatant
according to the manufacturer’s instructions. This assay utilizes the
formation of chromogenic complex formed between calcium ions
and O-cresolphtalein. The measured contents were normalized to
the DNA contents of the pellets.
Histology
Pellets cultured in vitro for 3 weeks or harvested from the in vivo
study were ﬁxed in 4% paraformaldehyde solution for 3 h, then
dehydratedwith 100% ethanol, washedwith xylene, and embedded
with parafﬁn. Sections with a thickness of 4 mmwere cut from the
parafﬁn block and coated on the glass slide. Safranin-O staining for
proteoglycan, and Alizarin red staining for mineralization were
performed. For Safranin-O staining, sections were deparafﬁnized
with xylene and ethanol, treatedwith aqueous Safranin-O (0.1%) for
30 min, and washed with distilled water. For Alizarin red staining,
specimens were stained with 2% Alizarin red solution (Junsei
Chemical, Tokyo) for 10 min, and washed with distilled water.
GenBank sequences
Human gene sequences were obtained from GenBank (accession
nos. AB081589 for SOX-5, AF309034 for SOX-6, and Z46629 for SOX-9).
Table II
The transfection efﬁciency of each subset
Transfected gene Vector SOX-5 SOX-6 SOX-9 SOX-5, -6, -9
Mean percentage
of transfected
cells [95% CI]
83.7
[77.9, 89.5]
76.7
[68.9, 84.5]
66.7
[56.3, 75.1]
74.9
[71.1, 78.7]
76.8
[73.8, 79.8]
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All quantitative data are expressed as the group means and 95%
conﬁdence intervals. Statistical analysis was performed using
analysis of variance followed by Dunnett’s correction for multiple
comparisons and ManneWhiney U test using SPSS software (SPSS,
Inc., Chicago, IL, USA). Signiﬁcance was set at a P< 0.05.
Results
Transfection of SOX-5, -6, and -9 into ASCs
The efﬁciency of transfection was investigated by ﬂuorescence
microscopy and ﬂuorescence-activated cell sorting (FACS) analysis
24 h after microporation. The gene transfection efﬁciency was high
for all groups; greater than two-thirds of cells were transfected
[Fig. 1(A), Table II]. The ﬂuorescence was detectable in the cultured
pellet 21 days after transfection [Fig. 1(B)].
Expression of the SOX trio gene and protein
In order to determine whether or not expressions of the trans-
fected genes and proteins still occur after a 3-week in vitro pellet
culture, real-time PCR and Western blotting were performed. Even
after 21 days, ASCs transfected with SOX-5, SOX-6, or SOX-9 had
a 100- to 550-fold greater gene expression of SOX-5, SOX-6, or SOX-9
when compared with the control (P< 0.0001, <0.0001, ¼0.011
respectively).When the SOX triowere co-transfected, each genewas
expressed in a greater amount than in the control (P¼ 0.041, 0.023,
0.045 respectively), although the level of expressionwas lower than
in single gene transfer [Fig. 2(A)]. The SOX-5, SOX-6, and SOX-9Fig. 1. Transfection was demonstrated by ﬂuorescence microscopy. ASCs transfected with p
24 h after transfection (A) and 21 days after transfection and pellet culture (B). 4',6-diam
ﬂuorescent protein (GFP) ﬂuorescent imaging (green).proteinwas clearly detected in ASCswith single transfection of each
gene, and more weakly detectable in ASCs with co-transfection of
the SOX trio. These results showed that the transfected genes were
continuously expressed up to 3 weeks of in vitro culture [Fig. 2(B)].
DNA and GAG levels
The amount of DNA and GAG was measured to assess the cell
number and the production of chondroid extracellular matrix. The
DNA content of all groups was between 0.4 and 0.6 mg, with no
signiﬁcant difference in theDNA levels among subsets. These results
indirectly showed that gene transfection did not have a signiﬁcant
effect on cell number [Fig. 3(A)]. GAG level normalized to DNA
signiﬁcantly increased by 4.2-fold when SOX trio genes were
co-transfected (P¼ 0.007) and by 3.8-fold when pellets were
treated with TGF-b2 and BMP-7 (P¼ 0.015). Other subsets with
single gene transfer of SOX-5, -6, and -9 did not show a signiﬁcant
elevation in the GAG level normalized to DNA [Fig. 3(B)]. Safranin-O
staining, which detects proteoglycan synthesis, showed intense
metachromasia with SOX trio co-transfection, corroborating the
results of the GAG analysis [Fig. 3(C)]. The results above show that
the chondrogenic differentiation of ASCs as demonstrated by GAG
synthesis is enhanced only when the SOX trio genes are co-
transfected.EGFP-C1 without interposed gene, SOX-5, SOX-6, SOX-9, and all three genes (SOX trio):
idino-2-phenylindole (DAPI) staining (blue, indicating nuclei) was merged with green
Fig. 2. Transfection of SOX-5, -6, and -9 elevated mRNA and protein expression of transfected gene. Gene (A) and protein (B) expression of SOX-5, SOX-6, and SOX-9 in ASCs
transfected with pEGFP-C1 without interposed gene (vector), SOX-5, SOX-6, SOX-9, and all three genes (SOX-5, -6, and -9), and in ASCs treated with TGF-b2 and BMP-7 (TGFþ BMP)
after 21 days of in vitro culture. N¼ 3, CI: conﬁdence interval.
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Gene expression of COL2A1, the chondrogenic marker, signiﬁ-
cantly increased by nine-fold when all three SOX genes were
co-transfected (P¼ 0.045) and by seven-fold when pellets were
treated with TGF-b2 and BMP-7 (P¼ 0.145). Transfection of a singleFig. 3. DNA level was unaffected while GAG was elevated by SOX trio co-transfection in ASCs
transfected with pEGFP-C1 without interposed gene (vector), SOX-5, SOX-6, SOX-9, and all th
days of in vitro culture. N¼ 5, CI: conﬁdence interval.gene transfer of SOX-5, -6, or -9, however, was not as effective in
inducing chondrogenic differentiation of ASCs [Fig. 4(A)]. COL1A1
mRNA expression, which signiﬁes inadequate differentiation,
signiﬁcantly increased with the treatment of TGF-b2 and BMP-7
(P¼ 0.015), while not changing signiﬁcantly in other subsets,
including SOX trio co-transfection [Fig. 4(A)]. COL10A1 gene. DNA levels (A), GAG levels normalized to DNA (B), and Safranin-O staining of ASCs (C)
ree genes (SOX trio), and in ASCs treated with TGF-b2 and BMP-7 (TGFþ BMP) after 21
Fig. 4. Chondrogenic marker genes and proteins were enhanced by SOX trio co-transfection. Gene expression of COL2A1, COL1A1, and COL10A1 (A), Western blotting for type II
collagen, type I collagen and type X collagen (B) in ASCs transfected with pEGFP-C1without interposed gene (vector), SOX-5, SOX-6, SOX-9, and all three genes (SOX trio), and in ASCs
treated with TGF-b2 and BMP-7 (TGFþ BMP) after 21 days of in vitro culture. N¼ 3, CI: conﬁdence interval.
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with TGF-b2 and BMP-7 (P¼ 0.024), but did not change with SOX
trio co-transfection [Fig. 4(A)]. These gene expression results show
that SOX trio co-transfection enhances COL2A1, while not increasing
COL1A1 and COL10A1, as occurs with TGF-b2 and BMP-7 treatment.
Enhancement of chondrogenic marker protein by SOX trio
co-transfection
Protein expression of types II, I, and X collagen was conﬁrmed
using Western blotting. Type II collagen dramatically increased
with co-transfection of SOX trio, which was greater than induced
with TGF-b2 and BMP-7 treatment. Type I collagen was detected in
all subsets, and increased in ASCs transfected with SOX-5 and SOX-
6, and in ASCs treated with TGF-b2 and BMP-7. Type X collagen
expression was decreased in ASCs with SOX trio co-transfection
while it remarkably increased with TGF-b2 and BMP-7 treatment
[Fig. 4(B)]. These results of protein expression further conﬁrmed
that SOX trio co-transfection increases chondrogenesis and blocks
hypertrophy of ASCs.
Persistent proteoglycan and reduced calciﬁcation in in-vivo
transplanted ASCs co-transfected with SOX trio
The pellets of each subset were ectopically transplanted into SCID
mice to determinewhether or not transfection of SOX genes reduces
mineralization and vascular invasion of ASC pellets in vivo. Three-
week explants of ASCs co-transfectedwith the SOX triodemonstrated
still abundant proteoglycan from Safranin-O staining, and revealed
a signiﬁcantly reduced mineralization from Alizarin red staining
compared with the control pellets. In addition, the measured GAG
level was three-fold greater (P¼ 0.037) and calcium contents lower
by 35% (P¼ 0.037) in ASCs co-transfectedwith the SOX trio compared
with the control (Fig. 5). These results suggested that SOX trio
transfection enhanced the in vivo chondrogenic potential of ASCs.
Discussion
The overall results showed that non-viral transfection of SOX trio
greatly enhanced chondrogenesis from ASCs, while decreasinghypertrophy. These ﬁndings raise the possibility of using the method
in cartilage tissue engineering. Thenecessityof using all three genes at
the same time was also veriﬁed as statistically signiﬁcant enhance-
ment was achieved only when all three factors were transfected.
Previous studies have demonstrated the effectiveness of using the
gene transferof the SOX trio in enhancing chondrogenicdifferentiation
from several cell sources. Over-expression of SOX-9 by gene transfer
enhanced the expression of proteoglycan and type II collagen in
a dose-dependent manner in normal and osteoarthritic AC33. Retro-
viral transduction of SOX trio enhanced re-expression of chondrocyte
phenotypes in passaged osteoarthritic human articular chon-
drocytes37. The combination of the SOX trio (SOX-5, -6, and -9) has
provided enough signal to induce permanent cartilage from embry-
onic stem cells. In the process, over-expression of the SOX trio sup-
pressed chondrocyte hypertrophy and osteogenic differentiation,
while promoting chondrogenic differentiation30. Our results demon-
strated the effectiveness of the SOX trio gene transfer also in ASCs.
We successfully induced chondrogenesis using non-viral
method, unlike from previous studies which used virus-mediated
gene transfer30,36,37. While non-viral gene transfers, which include
physical and chemical means, are a safe method for clinical appli-
cation, these methods have been fraught with the problem of low
transfection efﬁciency. The remarkable ﬁnding in our study was the
very high efﬁciency of transfection (approximately 70%), as
demonstrated by the FACS study. This high efﬁciency raises the
potential for clinical applications. The half-life of a transgene is
usually short in electroporation, as noted by gradual decrease in the
expression of transfected genes in ASCs. In addition, as the trans-
fected genes are transcription factors, translated protein is
supposed to be rapidly destroyed. Nevertheless, greater amount of
proteoglycan synthesis and still higher chondrogenic gene
expression at day 21 demonstrate the effectiveness of SOX trio gene
transfection. There is also a possibility that the transfected SOX
genes have triggered expression of endogenous SOX genes. It is not
certain at this point whether transient expression of chondrogenic
factors as in non-viral or adenoviral gene transfer, or permanent
gene expression as in retroviral gene transfer, would be more
beneﬁcial to cartilage tissue engineering. However, in view of the
safety and applicability, non-viral gene transfer used in our study
provides a clinically applicable method for gene transfer.
Fig. 5. Persistent proteoglycan and reduced calciﬁcation were observed in in-vivo transplanted ASCs co-transfected with SOX trio. Pellets were implanted in subcutaneous pockets of
SCID mice for 3 weeks: Safranin-O staining and Alizarin red staining in ASCs transfected with pEGFP-C1 without interposed gene (vector), all three genes (SOX trio). Scale bars are
equal to 500 mm (A). The results of GAG assay and calcium assay are also presented (B).
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drogenesis of adult stem cells have primarily focused on gene
transfer of growth factors, such as TGF-bs, IGF, and BMPs38e44. As
growth factors are secreted outside, their effects can become
uncontrollable, depending on the local concentrations. In
contrast, transcription factors are the effector molecules of
growth factors. Thus they are not secreted, and act inside of cells.
Though the transfection of SOX-9 was sufﬁcient to enhance
chondrogenesis from MSCs in a previous murine study31, and
effectively increased proteoglycan and type II collagen in human
osteoarthritic cartilage36, our results clearly demonstrated that
SOX-5 and SOX-6 are required, as well as SOX-9, to induce
effective chondrogenesis from human ASCs. Although it was out
of the scope of the current study to provide an answer to this, it
could be speculated that ASCs had intrinsically low activity of
SOX-5 and SOX-6.
The current study is the ﬁrst demonstration of the possibility of
using gene transfer of SOX trio genes for cartilage tissue engi-
neering from ASCs. Unlike in chondrogenic induction by growth
factors19,20, type I collagen did not increase and type X collagen
decreased, while strong chondrogenic differentiation was induced
by the gene transfer of the SOX trio in ASCs. A corollary study
should be performed to substantiate the results of the ectopic
model tested in this study by using an orthotopic model of carti-
lage healing, which will clarify whether the transient expression of
the SOX trio would be enough to produce AC of durable property
from ASCs in vivo. Nevertheless, this study provides a novel model
of the SOX trio gene transfer to ASCs that markedly enhances
chondrogenesis while suppressing hypertrophy. The results of this
study will make a valuable contribution to cartilage tissue engi-
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